Specificbiologics
1 known investors
Specific Biologics develops Dualase, a genome editing platform for in vivo therapeutic applications. The company is advancing a pipeline of therapies targeting CNS, lung, and liver indications caused by genetic drivers, using proprietary two-site mechanisms for precise DNA sequence removal, repair, and insertion.
BiotechDeep TechMedical Devices